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Introduction: the IL-23/IL-17 axis in spondyloarthritis
In the present issue of Arthritis Research & Th  erapy, 
Heiner Appel and colleagues from Berlin present an 
important histological study on IL-17-producing cells in 
spondyloarthritis (SpA) [1]. Th  e IL-23/IL-17 axis has 
become a major focus of SpA research based on three key 
observations. Firstly, the ankylosing spondylitis subset of 
SpA is associated with genetic polymorphisms of the IL-23 
receptor – the protective R381Q gene variant has recently 
been demonstrated to impair Th   17 responses [2,3]. 
Secondly, the unfolded protein response – a cellular stress 
programme that can be initiated by HLA-B27 misfolding 
– strongly increases the production of IL-23 [4]. Th  irdly,  a 
recent proof-of-concept trial with an anti-IL-17A 
monoclonal antibody showing good eﬃ   cacy  in  active 
ankylosing spondylitis provided the ﬁ  rst direct evidence 
that IL-17 plays an important role in SpA pathogenesis [5].
Identifi  cation of IL-17-producing cells
Th  e IL-23/IL-17 axis was originally described in T-cell 
biology, where IL-23 is a crucial factor in the so-called 
Th  17 response. Th  17 cells have been demonstrated to 
play a pathogenic role in many experimental autoimmune 
diseases. In human SpA, several studies enumerating 
Th  17 cells in SpA have yielded partially conﬂ  icting 
results – but a recent report convincingly demonstrated 
an increased presence and IL-17 production of KIR3DL2+
T cells responsive to HLA-B27 homodimers in blood and 
synovial ﬂ  uid [6]. Before postulating that these cells are 
the major IL-17 producers in SpA, however, one should 
consider the fact that many other cell types besides 
canonical Th  17 cells express the IL-23 receptor and 
respond to IL-23 by producing IL-17.
Based on the original demonstration that IL-23 is able 
to induce IL-17 production in RAG-deﬁ  cient mice that 
lack both B cells and T cells [7], there is now also ample 
evidence in humans that IL-17 is produced by γδ T cells, 
mast cells, neutrophils, and innate lymphoid cells between 
others. Th  is concept urged translational researchers to 
reassess the cellular source of IL-17 in the primary target 
tissues of a various diseases. Several seminal studies have 
identiﬁ  ed noncanonical IL-17-producing cells in tissue 
inﬂ   ammation, including mast cells in rheumatoid 
synovitis and psoriasis and innate lymphoid cells in 
inﬂ  ammatory bowel disease [8-10]. It is in this context 
that Appel and colleagues made the crucial observation 
that innate immune cells rather than canonical T cells 
express IL-17 in axial spondyloarthritis. Th  eir extensive 
histological analysis of zygoapophyseal joints clearly 
demonstrates that CD15+ neutrophils and myeloperoxidase-
positive myeloid cells, but not classical T cells, are the 
major cellular sources of IL-17 in the inﬂ  amed  bone 
marrow. Th   ese data corroborate with emerging evidence 
that mast cells and neutrophils, but not T cells, are also 
the major cellular source of IL-17 in peripheral SpA. 
Taken together, these studies emphasise the relevance of 
direct analysis of aﬀ  ected tissues and postulate a role for 
innate IL-17-producing cells in SpA.
Production of IL-17-related cytokines
Th  e observations of Appel and colleagues urge us to 
revisit the pathobiology of the IL-23/IL-17 axis in SpA. 
Firstly, we will have to investigate which cytokines and 
transcription factors are responsible for this innate IL-17 
response. Although it is tempting to propose a role for 
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The past decade has witnessed signifi  cant progress in 
revealing an important role for IL-17 in the pathogenesis 
of several immune-mediated infl  ammatory diseases. 
Recent studies have provided new insights into the 
cellular source of IL-17, originally identifi  ed as the 
signature cytokine of a distinct CD4+ T-cell subset known 
as Th17. Accumulating evidence suggests that the 
majority of the IL-17 released in infl  ammatory arthritis 
is produced by innate immune cells rather than T cells. 
Understanding molecular mechanisms behind these 
early innate immune responses will be the key to 
designing rational therapies targeting these important 
infl  ammatory pathways.
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Th   17 biology, this remains to be formally demonstrated 
and would not suﬃ   ce to explain why SpA displays an 
innate rather than acquired IL-17 response.
Secondly, it will be crucial to determine which 
cytokines are exactly produced by these innate IL-17-
producing cells. Th  is includes better characterisation of 
the IL-17 isotypes, as the reagents used in Appel and 
colleagues’ study and most other reports do not allow 
one to formally discriminate IL-17A from IL-17F. A 
related cytokine of major interest is IL-22 as its produc-
tion is also IL-23 dependent and closely related to IL-17 
in T cells. IL-22 provides a unique signal directionality 
from the immune system to the stromal tissue as the 
IL-22 receptor is exclusively expressed on mesenchymal 
cells. Th  e  eﬀ  ect of IL-22 on enterocytes can be protective 
in colitis whereas it contributes to keratinocyte hyper-
plasia in psoriasis models. Considering the prototypical 
stromal alterations in SpA, it will be important to 
determine which innate IL-17-expressing cells can also 
produce IL-22 [8].
Implications for targeted therapies
Th  e previously mentioned issues may have direct rele-
vance for targeted therapies. If innate IL-17-expressing 
cells produce other IL-23-dependent pathogenic factors, 
would IL-23 targeting then be more useful than an anti-
IL-17A monoclonal antibody in SpA [5]? Or, in contrast, 
would it be wiser to target selectively IL-17 without 
impairing IL-22 production as suggested by some colitis 
models? Could we imagine trying to target a speciﬁ  c 
pathogenic IL-17-producing cell population – for 
example, using imatinib to deplete c-kit-positive mast 
cells and innate lymphoid cells – rather than the cyto-
kines they produce in order to leave the protective IL-17 
production untouched [11]? It is mainly in the context of 
selective therapeutic targeting that the work of Appel and 
colleagues set a ﬁ  rst, but crucial, step in characterisation 
of the phenotype, developmental and transcriptional 
requirements, and function of innate IL-17-producing 
cells in SpA.
Abbreviations
IL, interleukin; SpA, spondyloarthritis; Th, T-helper type.
Competing interests
The authors declare that they have no competing interests.
Published: 24 June 2011
References
1.  Appel H, Maier R, Wu P, Scheer R, Hempfi  ng A, Kayser R, Thiel A, Radbruch A, 
Loddenkemper C, Sieper J: Analysis of interleukin-17+ cells in facet joints of 
patients with spondyloarthritis suggests that the innate immune pathway 
might be of greater relevance than the Th17 mediated adaptive immune 
response. Arthritis Res Ther 2011, 13:R95.
2.  Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F, Tosi I, 
Capon F, Trembath RC, Peris K, Nestle FO:The IL-23R R381Q gene variant 
protects against immune-mediated diseases by impairing IL-23-induced 
Th17 eff  ector response in humans. PLoS One 2011, 6:e17160.
3.  Sarin R, Wu X, Abraham C: Infl  ammatory disease protective R381Q IL23 
receptor polymorphism results in decreased primary CD4+ and CD8+ 
human T-cell functional responses. Proc Natl Acad Sci U S A 2011, 
108:9560-9565.
4.  DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA: HLA-B27 
misfolding and the unfolded protein response augment interleukin-23 
production and are associated with Th17 activation in transgenic rats. 
Arthritis Rheum 2009, 60:2633-2643.
5.  Baeten D, Sieper J, Emery P, Braun J, van der Heijde D, McInnes I, van Laar J, 
Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Bertolino A, 
Wright A, Hueber W: The anti-IL17A monoclonal antibody secukinumab 
(AIN457) showed good safety and effi   cacy in the treatment of active 
ankylosing spondylitis. Arthritis Rheum 2010, 62:2840-2841.
6.  Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, Cummings F, 
McMichael A, Kollnberger S: Th17 cells expressing KIR3DL2+ and responsive 
to HLA-B27 homodimers are increased in ankylosing spondylitis. 
J Immunol 2011, 186:2672-2680.
7.  Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, 
Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F: 
Diff  erential activity of IL-12 and IL-23 in mucosal and systemic innate 
immune pathology. Immunity 2006, 25:309-318.
8.  Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, 
McInnes IB: Mast cell express IL-17A in rheumatoid arthritis synovium. J 
Immunol 2010, 184:3336-3340.
9.  Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, 
Shah P, Kaplan MJ, Bruce AT: Mast cell and neutrophils release IL-17 through 
extracellular trap formation in psoriasis. J Immunol 2011. [Epub ahead of 
print]
10.  Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen 
NJ, Travis SP, Powrie F: IL-23-responsive innate lymphoid cells are increased 
in infl  ammatory bowel disease. J Exp Med 2011, 208:1127-1133.
11.  Eklund KK, Remitz A, Kautiainen H, Reitamo S, Leirisalo-Repo M: Three 
months treatment of active spondyloarthritis with imatinib mesylate: an 
open-label pilot study with six patients. Rheumatology 2006, 45:1573-1575.
doi:10.1186/ar3351
Cite this article as: Yeremenko N, Baeten D: IL-17 in spondyloarthritis: is the 
T-party over? Arthritis Research & Therapy 2011, 13:115.
Yeremenko and Baeten Arthritis Research & Therapy 2011, 13:115 
http://arthritis-research.com/content/13/3/115
Page 2 of 2